We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-18.32%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$875M
AUM Growth
-$123M
Cap. Flow
+$83.4M
Cap. Flow %
9.54%
Top 10 Hldgs %
28.77%
Holding
95
New
7
Increased
32
Reduced
30
Closed
6

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$14M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$11.4M
3
CNC icon
Centene
CNC
+$10.7M
4
BIIB icon
Biogen
BIIB
+$9.57M
5
UNH icon
UnitedHealth
UNH
+$9.35M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$10.1M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.4M
3
INCY icon
Incyte
INCY
+$7.17M
4
LOXO
Loxo Oncology, Inc
LOXO
+$6.07M
5
EXEL icon
Exelixis
EXEL
+$5.39M

Sector Composition

Rank Sector Weight
1 Healthcare 93.94%
2 Energy 0.12%
3 Technology 0.11%
4 Financials 0.09%
5 Communication Services 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
26
Eli Lilly
LLY
$1.06T
$14.3M 1.64%
123,695
-46,305
-27% -$5.17M
KYNB
27
Kyntra Bio
KYNB
$29.4M
$14M 1.6%
12,069
+2,021
+20% +$2.27M
CNC icon
28
Centene
CNC
$32.5B
$13.8M 1.58%
240,000
+160,000
+200% +$10.7M
CELG
29
DELISTED
Celgene Corp
CELG
$13.8M 1.58%
215,698
+35,000
+19% +$2.58M
SGEN
30
DELISTED
Seagen Inc. Common Stock
SGEN
$13.7M 1.57%
242,198
+62,198
+35% +$3.9M
GKOS icon
31
Glaukos
GKOS
$10.6B
$13.5M 1.54%
240,579
-40,700
-14% -$2.45M
BSX icon
32
Boston Scientific
BSX
$71.5B
$13.4M 1.53%
377,908
+39,940
+12% +$1.45M
AGN
33
DELISTED
Allergan plc
AGN
$13.2M 1.51%
98,600
+28,555
+41% +$4.68M
SAGE
34
DELISTED
Sage Therapeutics
SAGE
$13.2M 1.5%
137,339
+12,600
+10% +$1.44M
SGMO
35
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$12.7M 1.45%
1,103,957
-93,400
-8% -$1.16M
GILD icon
36
Gilead Sciences
GILD
$165B
$11.8M 1.35%
188,200
-1,447
-0.8% -$101K
BLUE
37
DELISTED
bluebird bio
BLUE
$11.7M 1.34%
+9,098
New +$14M
LIVN icon
38
LivaNova
LIVN
$4.2B
$11M 1.26%
120,600
+25,600
+27% +$2.75M
IOVA icon
39
Iovance Biotherapeutics
IOVA
$2.87B
$10.7M 1.22%
1,205,495
-85,000
-7% -$820K
EW icon
40
Edwards Lifesciences
EW
$51.7B
$10.2M 1.17%
199,755
-90,000
-31% -$4.55M
AERI
41
DELISTED
Aerie Pharmaceuticals
AERI
$10.1M 1.16%
280,000
+100,000
+56% +$4.69M
ARRY
42
DELISTED
Array Biopharma Inc
ARRY
$9.94M 1.14%
697,370
-71,000
-9% -$1.08M
WBA
43
DELISTED
Walgreens Boots Alliance
WBA
$9.91M 1.13%
145,000
– –
MYOK
44
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$9.25M 1.06%
189,322
+1,050
+0.6% +$57.8K
ALNY icon
45
Alnylam Pharmaceuticals
ALNY
$29.3B
$8.13M 0.93%
111,550
-60,400
-35% -$4.65M
XNCR icon
46
Xencor
XNCR
$1.55B
$7.9M 0.9%
218,537
+8,683
+4% +$319K
COR icon
47
Cencora
COR
$61.2B
$7.55M 0.86%
101,520
– –
ITCI
48
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.52M 0.86%
659,982
+5,000
+0.8% +$80.7K
MGNX icon
49
MacroGenics
MGNX
$257M
$6.89M 0.79%
542,186
+200,600
+59% +$3.36M
IMMU
50
DELISTED
Immunomedics Inc
IMMU
$6.85M 0.78%
480,330
+55,000
+13% +$1.09M
1
2
3 4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Rhenman & Partners Asset Management held 95 positions worth $875M, down 12% from $998M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $83.4M of net new capital in Q4 2018, opening 7 new positions and adding to 32 existing holdings. Its largest new stake was bluebird bio: 9,098 shares worth $11.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier, followed by Energy and Technology.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $8.4M trimmed.

  • Rhenman & Partners Asset Management's largest Q4 2018 buy was bluebird bio: 9,098 shares worth $11.7M.
  • Rhenman & Partners Asset Management added most to Neurocrine Biosciences in Q4 2018, an estimated $11.4M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2018 reduction was BioMarin Pharmaceuticals, cutting an estimated $8.4M.
  • Rhenman & Partners Asset Management fully exited Aetna Inc in Q4 2018, selling an estimated $10.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $875M portfolio in Q4 2018.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 6 in Q4 2018.
  • Rhenman & Partners Asset Management's portfolio value fell 12% quarter-over-quarter to $875M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2018, filed 5 Feb 2019.